Human cord blood hematopoietic progenitor cell

Human cord blood hematopoietic progenitor cells consist of hematopoietic progenitor cells, monocytes, lymphocytes, and granulocytes from human cord blood. They are used during allogeneic unrelated and related hematopoietic stem cell transplantation procedures in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. Human umbilical cord is a rich source of hematopoietic stem cells and progenitor cells that are capable of proliferation in vitro. Active and viable hematopoietic progenitor cells, or hematopoietic stem cells (HSCs) express the cell surface marker CD34 which is critical for cell identification ^A32216. Upon division and maturation at the bone marrow following intravenous administration to the patient, hematopoietic progenitor cells enter the systemic circulation to restore blood counts and function FDA Label.

After the first cord blood transplant in 1988 in a patient with Fanconi anemia ^A32220, the use of umbilical cord blood transplantation was increased in clinical settings. Human cord blood hematopoietic progenitor cells can be collected from both related or unrelated donors. The unrelated donor transplant setting has several advantages over related donor transplant and bone marrow transplantation; it allows shorter time to transplant and tolerance of 1–2 human leukocyte antigen mismatch due to expanded donor pool, which increases the chance of finding a suitable donor, particularly in patients requiring urgent transplantation ^A32219. Other advantages of HSC transplantation include a lower risk of transmitting infections by latent viruses and improved targeting of ethnic minorities increased pool of rare haplotypes ^A32219. Umbilical cord blood cell transplantation was also associated with reduced incidence and severity of graft versus host disease (GVHD) thus improved survival rates of transplant patients compared to allogeneic bone marrow transplant setting, which may be due to "naive" nature of lymphocytes ^A32223. Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use.